

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1616
Kowalski, James et al. Examiner: Yu, Hong
INTERNATIONAL APPLICATION NO: PCT/EP2005/000400
FILED: January 17, 2005
U.S. APPLICATION NO: 10/586059
35 USC §371 DATE: May 08, 2007
FOR: Direct Compression Formulation and Process

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed March 13, 2008 and September 20, 2010.
- ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- ☐ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- ☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- ☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A/B.

- ☐ The listed references were cited in the international stage search report and copies are enclosed herewith except for the US patents/applications.
- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-1422

Date: *May 9, 2011*

Respectfully submitted,



Stephen Johnson
for Applicant
Reg. No. 45,916

CASE PAT033554-US-PCT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1616
Kowalski, James et al. Examiner: Yu, Hong
INTERNATIONAL APPLICATION NO: PCT/EP2005/000400
FILED: January 17, 2005
U.S. APPLICATION NO: 10/586059
35 USC §371 DATE: May 08, 2007
FOR: Direct Compression Formulation and Process

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-1422
Date: *May 9, 2011*

Respectfully submitted,



Stephen Johnson
for Applicant
Reg. No. 45,916